Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kährs BondCo publishes annual report for 2023

Kährs BondCo AB (publ) announces that the company's annual report for 2023 in Swedish is now available on Kährs Group's website (kahrsgroup.com ) and is also attached to this press release.This information is information that Kährs BondCo AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication at 08:00 am CET on April 18, 2024.   For further information, please contact:Johan Magnusson, President and CEOPhone: +46 70 540 13 96 johan.magnusson@kahrs.com Andreas Larsson, CFO

Invitation to conference call of Cloetta´s interim report Q1 2024

Cloetta  AB will publish the interim report for the period 1 January – 31 March 2024 on Friday 26 April 2024 at 7.30 a.m. CEST. Following this report Cloetta will organise a conference call with web presentation for media and the financial community at 10.00 am.President and CEO Henri de Sauvage Nolting and CFO Frans Rydén will present and comment on the report. After the presentation there will be time for questions, both on the phone and in the web presentation. It is possible to preregister questions via email to ir@cloetta.com. Time for the publication of

Neste to publish its first quarter results on 25 April 2024

Neste Corporation, Press Release, 18 April 2024 at 9 a.m. (EET) Neste will publish its first quarter 2024 results on Thursday, 25 April 2024 at approximately 9 a.m. (EET). The release will be available on the Neste website  immediately after publishing. A conference call in English for investors and analysts will be held on 25 April 2024, at 3 p.m. Finland / 1 p.m. London / 8 a.m. New York. In order to receive the participant dial in numbers and a unique personal PIN, participants are requested to register using this link: https://register.vevent.com/

AQ Group AB (publ), interim report January - March, 2024

First quarter, January-March 2024 in brief   · Higher delivery precision and productivity improves profitability · Net sales decreased by 1% to SEK 2,225 m (2,253) · Operating profit (EBIT) increased by 15% to SEK 223 m (194) · Profit before tax (EBT) increased by 20% to SEK 221 m (184) · Profit margin before tax (EBT %) was 9.9% (8.2) · Profit after tax amounted to SEK 185 m (159) · Cash flow from operating activities amounted to SEK 244 m (225) · Earnings per share before dilution amounted to SEK 10.06 (8.61) · Equity ratio was 64% (55) · The Board of

BioArctic publishes the Annual Report for 2023

Stockholm April 18, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for 2023 has been published.The Annual Report, which is attached, can also be downloaded from the company’s website, www.bioarctic.se/en (Investors/Financial reports and presentations).   ---   For further information, please contact: Oskar Bosson, VP Communications and Investor RelationsE-mail: oskar.bosson@bioarctic.comPhone: +46 70 410 71 80    This information is information that BioArctic AB (publ) is obliged to make public pursuant to the Swedish

Invitation to Exel Composites’ Q1 2024 financial results briefing on 25 April 2024

EXEL COMPOSITES PLC          INVESTOR NEWS          18 APRIL 2024 at 9:00 EETExel Composites will publish its Q1 2024 Business Review on Thursday 25 April 2024 at approximately 9:00 EET. Investors, analysts and journalists are invited to participate in the financial results briefing at 12:30 EET on the same day. The briefing will be hosted by President and CEO Paul Sohlberg and CFO Mikko Rummukainen.   The briefing will be organized online. To participate in the event, please register in advance by sending an email to investor@exelcomposites.com by Wednesday 24 April 2024. A link to

Polygiene Group AB (publ.) publishes Annual Report for 2023

The Annual Report 2023 for Polygiene Group AB (publ.) is now available at the company’s site ir.polygiene.com.  The Annual General Meeting will be held Thursday 16 May 2024 at 13.00 at STUDIO, Nordenskiöldsgatan 24, in Malmö.To download the annual report, visit ir.polygiene.com/financial-reportsFor more information contact:Niklas Blomstedt, CFOMobile: +46 (0) 70 663 21 26E-mail: niklas.blomstedt@polygiene.com                     Ulrika Björk, CEOMobile: +46 (0) 70 921 12 75E-mail: ulrika.bjork@polygiene.com This information was submitted for publication, through the agency

Metso supports sustainable mining development in Chile and introduces a unique circularity solution for mill liner recycling

Metso Corporation’s press release on April 18, 2024, at 9.00 AM EESTSustainable mining is a critical ambition in countries like Chile, the world’s leading copper producer. In response to the growing demands of its mining customers, Metso is strengthening its position as a supplier of a substantial range of sustainable solutions with the introduction of its unique circularity recycling solution for Megaliner™, Poly-Met™, and rubber liners in Chile. The solution enables the efficient separation of different liner materials so that the valuable rubber and steel components can either be

Director/PDMR Shareholding

18 April 2024   Hydro Hotel, Eastbourne, Plc (“Hydro Hotel” or the “Company”)   Director/PDMR Shareholding   Hydro Hotel, Eastbourne, Plc has been notified that, on 17 April 2024, C.P. Freeman, a Non-executive Director of the Company, acquired 500 ordinary shares of £1 each in the Company (“Ordinary Shares”) at a price of £9.99 per share. Following this acquisition, Mr. Freeman is interested in 9,500 Ordinary Shares, representing 1.58% of the Ordinary Shares in issue. The Directors of Hydro Hotel accept responsibility for the content of this announcement.

Genetic Analysis AS: Publication of Annual Report 2023

Oslo, Norway, April 18, 2024 - Genetic Analysis AS (the "Company", Ticker: GEAN) hereby publishes the Annual Report for the financial year of 2023. The Annual Report is available as an attached file to this release and on the Company's website (www.genetic-analysis.com).The company's auditor has stated in his auditor’s report on page 1 that there is material uncertainty related to going concern. The wording is reproduced below in full: Material Uncertainty Related to Going Concern“We draw attention to Note 25 in the financial statements, which indicates that the Company projects that

Interim report Q1, 2024: Strong growth in APAC and solid margins

First quarter · Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK. · Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas. · Sales per business area, in local currencies was +12% in Consumables, +8% in Technologies and -12% in Genetics. · Gross margin increased to 57.1% (56.8). · Operating income before depreciation and amortisation (EBITDA) increased to SEK 272 (262) million, giving an EBITDA margin of 32.4% (30.6). · Operating cash flow increased to SEK 198 million (160). · Net income

OKEA first quarter 2024 trading update

(Trondheim, 18 April 2024) OKEA ASA (OSE: OKEA) will publish its financial report for the first quarter of 2024 on Thursday 25 April at 06:00 (CET). This trading update is provided to summarise production and sales volumes and related topics and updates for the quarter.(Amounts in parentheses refer to previous quarter) First quarter 2024 production and sales Unit Q1 2024** Q4 2023***Total operating income MNOK 3,422 2,118Realised liquids price USD/boe* 82.0 83.4Realised

Olvi Group’s interim report for January–March 2024 – Profitability improved markedly; net sales and sales volume at the previous year’s level

OLVI PLC                  Interim report 18 April 2024 at 9 am Olvi Group’s interim report for January–March 2024 – Profitability improved markedly; net sales and sales volume at the previous year’s level. January–March 2024 · Sales volume increased by 0.9% to 205.1 (203.2) million litres. · Net sales increased by 0.7% and were EUR 130.4 (129.5) million. · Profitability improved significantly based on the performance of the Finland and Baltic Sea segments: the adjusted operating result increased by 12.6% to EUR 11.2 (10.0) million. · The equity ratio was 55.1% (50.7%).

Scape Technologies Introduces SCAPE CoCreator at Hannover Messe 2024: A Revolutionary 3D Robot Guidance Platform Designed to Simplify Robotic Automation

Today's industrial robotics, 3D Vision, and AI are often confined by costs, complexity, and limited accessibility and usability. Scape Technologies is revolutionizing this field by broadening the horizons of what is possible. At Hannover Messe 2024, Scape Technologies proudly introduce the SCAPE CoCreator, a 3D robot guidance platform that integrates advanced AI and 3D Vision technology with intuitive, no-code robot programming.A New Era of Automation: Introducing the SCAPE CoCreator Platform The SCAPE CoCreator platform embodies a leap forward in making robotic automation accessible to

Interim report 2024, January 1 – March 31

The first quarter saw a continued favourable revenue development. The Lab segment delivered strong organic growth whereas our pharmaceuticals business affected the Group negatively. The changing product mix resulted in lower margins. Work continued to optimise the capital structure and profit for the period improved.January – March 2024 Net revenue for the period was SEK 413.4 million (310.5), an increase of 33.1% On an organic basis, net revenue declined by 9.5%. Excluding pharmaceuticals, organic growth was 3.6%. EBITDA for the period was SEK 99.1 million (84.2) Profit/loss

EQT AB (publ) Q1 Announcement 2024

A promising start to 2024 - and to EQT’s fourth decade“EQT started the year with the successful completion of two fundraises, EQT X and EQT Future, with total commitments of more than EUR 25 billion. Investment activity continued at a good pace and, with transactions such as the IPO of Galderma, we expect a gradual increase in exit activity. Whilst the macroeconomic environment, financing conditions, and capital markets activity have improved, we continue to monitor geopolitical risks and macro developments, including interest rates, and maintain our focus on performance.”Highlights for

Aker ASA: Ex-dividend NOK 15.50 today

The shares in Aker ASA will be traded ex-dividend NOK 15.50 as from today, 18 April 2024. -ENDS- Investor contact:Fredrik Berge, Head of Investor Relations Aker ASATel: +47 450 32 090E-mail: fredrik.berge@akerasa.com Media contact:Atle Kigen, Head of Media Relations and Public Affairs Aker ASATel: +47 907 84 878E-mail: atle.kigen@akerasa.com This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

First quarter 2024 – EBITDA improvement from modest levels

Oslo, 18 April 2024 Elkem’s EBITDA in the first quarter 2024 improved compared to the preceding two quarters despite challenging market conditions. Commodity sales prices have improved during the quarter, but demand is still weak. There are signs of demand recovery, but the uncertainty is still significant. Elkem’s total operating income for the first quarter 2024 was NOK 7,961 million, which was in line with the preceding quarters, but down 18% from the first quarter 2023. Earnings before interest, taxes, depreciation and amortisation (EBITDA) was NOK 721 million, which was up from

Norconsult ASA - Annual Report 2023

Sandvika, 18 April 2024 (OSE: NORCO): Norconsult ASA has today published its audited Annual Report for 2023, including the Corporate Governance Report and its Sustainability Report for 2023. The Annual Report is also available in European Single Electronic Format (ESEF). The reports are attached to this release and available on the company’s website www.investor.norconsult.com. For further information, please contact: Investors: Elin Spieler, Head of Treasury and IR Manager, Elin.Spieler@norconsult.com                                                        Media: Henrik

Hansa Biopharma interim report January-March 2024

•    Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease •    Cash runway extended into 2026•    Evan Ballantyne joins Hansa Biopharma as Chief Financial OfficerLund, Sweden, April 18, 2024, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024 · Strong commercial performance. Total Q1 revenue of SEK 56m including product sales of SEK 47m – sales growth during Q1 2024 was driven

Tele2 interim report first quarter 2024

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) today announces its consolidated results for the first quarter 2024.Highlights · End-user service revenue of SEK 5.3 billion increased by 4% organically compared to Q1 2023 due to solid performance across operations. Total revenue of SEK 7.2 billion increased by 2% compared to Q1 2023. · Underlying EBITDAaL of SEK 2.6 billion increased by 2% organically compared to Q1 2023, as end-user service revenue growth exceeded the cost inflation. · Q1 2024 profit after financial items (EBT) of SEK 1.0 (1.1) billion. ·

Swedbank Economic Outlook: Recovery in sight

The Swedish economy will gradually enter a recovery phase this summer. Inflation will continue to fall and household real income will rise, although the labour market will weaken this year. The Riksbank will start cutting the policy rate in May, and fiscal policy will be more expansionary in 2025, according to Swedbank Economic Outlook.“The outlook for households is starting to improve. After two years of falling income, real disposable income will increase this year and will go up even more next year. Consumption will remain subdued for a while as the labour market weakens during the year,

There are no items matching the current filter
There are no more items matching the current filter
Back to top